Nephrology

Uzm. Dr. Mehmet Sezen

Doctor and researcher Bursa Şehir Hastanesi Bursa
Diabetes Mellitus, Type 2
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Diabetes Mellitus, Type 2 2 publications
    Source: OpenAlex / PubMed MeSHView publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyNephrologysaglik.gov.trFrom source
  • InstitutionBursa Şehir Hastanesisaglik.gov.trFrom source
  • Area of workDiabetes Mellitus, Type 2Extracted from 2 publications · Model version —From source
  • Publications37 publicationsORCID, OpenAlex, Europe PMCFrom source
  • ORCID0000-0001-5796-6445ORCIDFrom source
  • Last synchronised7 November 2026 00:03https://bursasehir.saglik.gov.tr/TR-606607/doktorlarimiz.html#mehmet-sezensaglik.gov.tr

Scientific work

Publications on Diabetes Mellitus, Type 2

37 publications

  1. Glycaemic control and complications in haemodialysis patients: the TURK-HEMODIAB Study

    Clinical kidney journal, 2026

    DOI 10.1093/ckj/sfaf120 PMID 41536569 1 citation (Europe PMC) Open-access full textSource: ORCID

  2. Finerenone Use in Heart Failure Patients with Type 2 Diabetes and Kidney Disease: An Analysis of the FINE-TURK Registry

    Cardiovascular Drugs and Therapy, 2026

    DOI 10.1007/s10557-026-07944-w PMID 42720721 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  3. Early laboratory trajectories and short-term tolerability after finerenone initiationin diabetic kidney disease: the multicenter FINE-TURK study

    BMC Nephrology, 2026

    DOI 10.1186/s12882-026-05259-4 PMID 42693414 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  4. Hyperkalemia risk with finerenone in diabetic kidney disease: a real-world analysis from the FINE-TURK cohort

    Clinical Kidney Journal, 2026

    DOI 10.1093/ckj/sfag227 PMID 42592375 Open-access full textSource: OpenAlex

  5. Hyperkalemia Risk After Finerenone Initiation in Diabetic Kidney Disease with Elevated Baseline Potassium: A Multicenter Cohort Study

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15155758 PMID 42589862 Open-access full textSource: OpenAlex

  6. Immunoglobulin A Nephropathy Associated with Systemic Disease: Clinical Spectrum and Long-Term Kidney Outcomes in a Single-Center Cohort

    Uludağ Üniversitesi Tıp Fakültesi Dergisi, 2026

    DOI 10.32708/uutfd.2027656 Open-access full textSource: ORCID

  7. Frailty Phenotype Among Older Adults Receiving SGLT-2 Inhibitors in a CKD-Predominant Population: A Prospective Cross-Sectional Study

    Medicina, 2026

    DOI 10.3390/medicina62101938 PMID 42942469 Open-access full textSource: ORCID

  8. Glomerular Capillary C4d Staining in Native Kidney Biopsies: Associations with Proteinuric Phenotype and Reduced Likelihood of Early Proteinuria Remission

    Diagnostics, 2026

    DOI 10.3390/diagnostics16172717 PMID 42739149 Open-access full textSource: ORCID

  9. Hyperkalemia Risk and Associated Factors After Finerenone Initiation in Patients with Diabetic Kidney Disease and Elevated Baseline Potassium: A Real-World Cohort Study

    2026

    DOI 10.20944/preprints202606.1710.v1 Open-access full textSource: ORCID

  10. Evaluation of clinicopathological features of renal biopsies in non-lupus rheumatic diseases: a university hospital experience

    Renal failure, 2026

    DOI 10.1080/0886022x.2026.2668784 PMID 42124467 Open-access full textSource: Europe PMC

View all 37 publications